Skip to main content

Table 3 Concomitant therapies

From: Clinical efficacy and tolerability of an immune-stimulant* constituted by inactivated bacterial bodies in the prophylaxis of infectious episodes of airways: a double blind, placebo-controlled, randomized, multicentre study

   

Placebo

Bacterial lysate

p

Antibiotics

No

Count

57 (64.8%)

55 (61.1)

 
 

Yes

Count

31 (35.2)

35 (38.9)

 

Anti-inflammatory drugs

No

Count

53 (60.2)

56 (62.2)

0.785

 

Yes

Count

35 (39.8)

34 (37.8)

(N.S.)

Antibiotics and anti-inflammatory drugs

No

Count

68 (77.3)

67 (74.4)

0. 659

 

Yes

Count

20 (22.7)

23 (25.6)

(N.S.)

Bronchodilators

No

Count

76 (86.4)

79 (87.8)

0. 659

 

Yes

Count

12 (13.6)

11 (12.2)

(N.S.)